Institute of Endocrinology, Rabin Medical Center-Beilinson Hospital, Petach-Tikva, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Endocrine. 2017 Dec;58(3):481-487. doi: 10.1007/s12020-017-1453-8. Epub 2017 Oct 20.
Limited data is available regarding the association between pre-admission thyroid function and prognosis of hospitalized patients treated for hypothyroidism.
Evaluate an association between thyroid stimulating hormone (TSH) levels and mortality in hospitalized levothyroxine-treated patients.
Observational data of patients admitted to medical wards between 2011 and 2013. TSH levels obtained up to 180 days prior to admission were stratified as follows: low (≤0.5 mIU/L), normal (0.5-5 mIU/L), high (>5 mIU/L).
Patients aged 60-80 years with available thyroid function tests were matched with controls without hypothyroidism.
All-cause mortality up to 66-months following discharge.
One thousand and fifty seven patients (73% females, mean (SD) age 71 ± 6 years) were matched with controls without hypothyroidism. Mean hospital stay and in-hospital mortality were not different between groups. Mortality risk at the end-of-follow-up was 41% (438/1057) and 37% (392/1057) for patients with and without hypothyroidism (p < 0.05). TSH levels were classified as follows: low, 84 patients (8%); normal, 667 patients (63%); high, 306 patients (29%). Length of hospitalization and in-hospital mortality were not different between TSH categories. Mortality risk at the end-of-follow-up was 30, 39, and 50% with low, normal and elevated TSH, respectively. Adjusted hazard ratio (95% CI) of mortality at the end-of-follow-up was of 2.2 (1.2-3.8) for high vs. low TSH levels, and 1.4 (1.1-1.9) for high vs. normal TSH levels.
In treated hypothyroid adult patients, increased TSH up to 6 months prior to admission is associated with increased mortality. Treatment should aim at achieving euthyroidism to improve survival.
关于住院治疗甲状腺功能减退症患者入院前甲状腺功能与预后的关系,目前仅有有限的数据。
评估住院接受左甲状腺素治疗的患者中促甲状腺激素(TSH)水平与死亡率之间的关系。
2011 年至 2013 年间,观察入住内科病房患者的数据。将入院前 180 天内获得的 TSH 水平分层如下:低(≤0.5mIU/L)、正常(0.5-5mIU/L)、高(>5mIU/L)。
年龄在 60-80 岁之间,有可用的甲状腺功能检查结果,并与无甲状腺功能减退症的对照组相匹配。
出院后 66 个月的全因死亡率。
1057 名患者(73%为女性,平均年龄 71±6 岁)与无甲状腺功能减退症的对照组相匹配。两组的平均住院时间和院内死亡率无差异。随访结束时的死亡率为 41%(438/1057)和 37%(392/1057),分别为有和无甲状腺功能减退症的患者(p<0.05)。TSH 水平分类如下:低,84 例(8%);正常,667 例(63%);高,306 例(29%)。TSH 类别之间的住院时间和院内死亡率无差异。随访结束时的死亡率风险分别为低 TSH 组的 30%、正常 TSH 组的 39%和高 TSH 组的 50%。调整后的随访结束时死亡率的风险比(95%CI)为高 TSH 组与低 TSH 组相比为 2.2(1.2-3.8),高 TSH 组与正常 TSH 组相比为 1.4(1.1-1.9)。
在接受治疗的甲状腺功能减退症成年患者中,入院前 6 个月内 TSH 升高与死亡率增加相关。治疗应旨在实现甲状腺功能正常以提高生存率。